- Home
- ES vs ZTS Comparison
ES vs ZTS Comparison
Compare ES & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ES | ZTS |
|---|---|---|
| Founded | 1927 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.9B | 29.0B |
| IPO Year | 1994 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ES | ZTS |
|---|---|---|
| Price | $67.92 | $78.72 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 16 | 16 |
| Target Price | $71.69 | ★ $88.62 |
| AVG Volume (30 Days) | 2.6M | ★ 2.9M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.71% | 2.73% |
| EPS Growth | ★ 100.88 | 10.05 |
| EPS | 1.75 | ★ 3.08 |
| Revenue | ★ $13,547,244,000.00 | $9,467,000,000.00 |
| Revenue This Year | $1.39 | N/A |
| Revenue Next Year | $4.80 | $1.57 |
| P/E Ratio | $38.19 | ★ $25.23 |
| Revenue Growth | ★ 13.83 | 2.28 |
| 52 Week Low | $62.72 | $68.92 |
| 52 Week High | $76.57 | $144.83 |
Technical Indicators
Market Signals| Indicator | ES | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 56.16 | 57.18 |
| Support Level | $66.67 | $72.36 |
| Resistance Level | $71.41 | $82.54 |
| Average True Range (ATR) | 1.29 | 1.72 |
| MACD | 0.36 | 0.09 |
| Stochastic Oscillator | 89.07 | 55.30 |
Price Performance
Historical ComparisonAbout ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric, gas, and water distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. It plans to sell Aquarion in 2026. The company exited most of its unregulated businesses in 2006.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.